Generic formulation from Amarin
Amarin Development AB, as part of an agreement with Watson
Pharmaceuticals, has developed a generic formulation of glipizide
extended release tablets.
Amarin corporation this week confirmed that its Swedish subsidiary Amarin Development AB, as part of an agreement with Watson Pharmaceuticals , has developed a generic formulation of glipizide extended release tablets.
Glipizide extended release tablets are marketed in the United States under the trade name Glucotrol XL by Pfizer. Watson announced in December 2002 that it had filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration seeking approval to market its generic version of Glucotrol XL tablets in 5 mg and 10 mg.
"This collaboration with Watson Pharmaceuticals demonstrates Amarin's capability of developing technically challenging products such as generic Glucotrol XL.
The Watson collaboration, plus other collaborations, including Tanabe for morphine in Japan, demonstrate the strength of Amarin's product development capability," said Rick Stewart, chief executive officer of Amarin.
Amarin, specialtiy pharmaceutical company, focuses on neurology and pain management.